From Basic Research to Cancer Drug: The Story of Cisplatin

if (n == null) The Scientist - From Basic Research to Cancer Drug: The Story of Cisplatin The Scientist 13[14]:11, Jul. 05, 1999 News From Basic Research to Cancer Drug: The Story of Cisplatin By Ricki Lewis Clinical Trial Results for Treating Cervical Cancer The April 15, 1999 issue of The New England Journal of Medicine (NEJM) brought great satisfaction to Barnett Rosenberg, a retired Michigan State University biophysicist who founded the Barros Resear

Written byRicki Lewis
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share


News

By Ricki Lewis

Clinical Trial Results for Treating Cervical Cancer

The April 15, 1999 issue of The New England Journal of Medicine (NEJM) brought great satisfaction to Barnett Rosenberg, a retired Michigan State University biophysicist who founded the Barros Research Institute in Holt, Mich., in 1982.1,2,3,4 Not many scientists can watch basic research blossom into a cancer treatment that has extended or saved thousands of lives. Rosenberg's keen observation in 1961 led, 18 years later, to Food and Drug Administration (FDA) approval of cisplatin. The drug's conception, gestation, and birth illustrate the scientific process and also the importance of following even the strangest of hunches.

Cisplatin revolutionized the treatment of testicular cancer, with success also against some ovarian and colon cancers. The trio of reports in the recent NEJM document remission in cervical cancer patients given cisplatin in combination with other treatments (See Box 1, in PDF file). ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies